Pharmaceutical

Vasomune wins FDA fast track designation for lung condition treatment

Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the prevention and treatment of ARDS in pneumonia.

May 29, 2024 - 04:00
Vasomune wins FDA fast track designation for lung condition treatment
Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the prevention and treatment of ARDS in pneumonia.
Read the original article

Tags:

Previous Article

HKUST researchers enhance performance of eco-friendly cooling applications by de...

Next Article

Self-amplifying RNA and vaccine innovation: getting from concept to clinic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In pigs, researchers show ultrasound could be used for 3D printing inside the body

In pigs, researchers show ultrasound could be used for ...

Dec 7, 2023

Morning Rounds: Have regulations on digital trackers in health care gone too far?

Morning Rounds: Have regulations on digital trackers in...

Dec 19, 2023

India’s ICMR and Ministry of AYUSH to research integrated medicine

India’s ICMR and Ministry of AYUSH to research integrat...

May 12, 2023